Boston Scientific Corporation (NYSE:BSX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Boston Scientific Corporation (NYSE:BSX) have received a consensus rating of “Moderate Buy” from the thirty analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, five have issued a hold rating, twenty-three have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $85.08.

Several research firms recently weighed in on BSX. Citigroup reduced their price objective on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, May 28th. BTIG Research reissued a “buy” rating and issued a $65.00 price target on shares of Boston Scientific in a report on Tuesday, June 16th. Oppenheimer set a $90.00 price target on shares of Boston Scientific in a report on Thursday, April 23rd. Piper Sandler restated an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Finally, The Goldman Sachs Group set a $71.00 price objective on Boston Scientific in a research report on Thursday, May 28th.

Boston Scientific Price Performance

Boston Scientific stock opened at $45.30 on Monday. Boston Scientific has a 12-month low of $44.44 and a 12-month high of $109.50. The stock has a market capitalization of $67.33 billion, a P/E ratio of 18.95, a P/E/G ratio of 0.87 and a beta of 0.56. The firm’s 50-day moving average is $54.71 and its two-hundred day moving average is $72.83. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period last year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts predict that Boston Scientific will post 3.36 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a stock repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling

In other news, Director David C. Habiger acquired 2,250 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the transaction, the director directly owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 9,800 shares of company stock worth $554,012 over the last three months. 0.34% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific in the fourth quarter valued at about $26,000. Colonial Trust Co SC boosted its stake in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 231 shares in the last quarter. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific in the fourth quarter valued at approximately $26,000. Finally, Bangor Savings Bank grew its stake in Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.